Results 31 to 40 of about 99,547,245 (298)
Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity [PDF]
, 2023 Combination therapy with anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) monoclonal antibodies (mAbs) has dramatically improved the prognosis of patients with multiple types of cancer, including renal cell ...Youki Ueda, Tomofumi Watanabe, Ueda, Youki, Sadahira, Takuya, Watanabe, Tomofumi, Togashi, Yosuke, Ishino, Takamasa, Araki, Motoo, Yosuke Togashi, Joji Nagasaki, Takamasa Ishino, Dansako, Hiromichi, Nagasaki, Joji, Takuya Sadahira, Hiromichi Dansako, Motoo Araki +15 morecore +2 more sourcesCTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade
Frontiers in Immunology, 2019 CTLA-4 is essential for immune tolerance. Heterozygous CTLA4 mutations cause immune dysregulation evident in defective regulatory T cells with low levels of CTLA-4 expression.Josselyn E. Garcia-Perez, Ryan M. Baxter, Daniel S. Kong, Richard Tobin, Martin McCarter, John M. Routes, James Verbsky, Michael B. Jordan, Cullen M. Dutmer, Elena W. Y. Hsieh, Elena W. Y. Hsieh +10 moredoaj +1 more sourcePeptide Blocking CTLA-4 and B7-1 Interaction
Molecules, 2021 Discovery of the B7 family immune checkpoints such as CTLA-4 (CD152), PD-1 (CD279), as well as their ligands B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1, CD274), and B7-DC (PD-L2, CD273), has opened new possibilities for cancer immunotherapy using monoclonal ...Stepan V. Podlesnykh, Kristina E. Abramova, Anastasia Gordeeva, Andrei I. Khlebnikov, Andrei I. Chapoval +4 moredoaj +1 more sourceMultiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma
Hepatology, EarlyView., 2022 Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims
Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara +29 morewiley +1 more sourceProteogenomic characterization of cholangiocarcinoma
Hepatology, EarlyView., 2022 Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims
Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding +18 morewiley +1 more sourceThe price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network [PDF]
, 2013 Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.Berking, Carola, Armin Justich (103646), Simone M. Goldinger, Daniela Göppner, Lucie M Heinzerling, Stephan Grabbe (103633), Clemens L. Bockmeyer, Robert Caroline, Thomas Eigentler, Christine Mateus (103663), Moos, Roger von, Loquai Carmen, Gerold Schuler, Dirk Schadendorf (103684), Christina Klein, Pätzold, Sylvie, Hundorfean, Gheorghe, Beatrice Schuler-Thurner, Göppner Daniela, Ralf Gutzmer (103628), Patrik Weder, Robert, Caroline, Bockmeyer, Clemens L., Dirk Schadendorf, Kaehler, Katharina C., Thomas Eigentler (103619), Katharina C. Kaehler, Gheorghe Hundorfean, Christine Mateus, Simone M. Goldinger (103594), Claus Garbe, Satzger, Imke, Ralf Gutzmer, Sylvie Paetzold (103676), Peter Mohr, Uwe Trefzer, Voskens, Caroline J, Carmen Loquai (103597), Bockmeyer Clemens L., Vaubel, Julia, Jens Ulrich, Wilhelm, Tabea, Bockmeyer, Clemens Luitpold, Julia Vaubel, Hauschild Axel, Mohr, Peter, Gheorghe Hundorfean (103642), Caroline J. Voskens, Justich, Armin, Hauschild, Axel, Fluck Michael, Loquai, Carmen, Schadendorf, Dirk, Beatrice Schuler-Thurner (103693), Satzger Imke, Göppner, Daniela, Carola Berking, Weder Patrik, Hundorfean Gheorghe, Eigentler, Thomas Kurt, Grabbe, Stephan, Ulrich Jens, Armin Justich, Rüdiger Hein (71354), Garbe Claus, Ulrich, Jens, Eigentler Thomas, Schadendorf Dirk, Gutzmer Ralf, Mateus Christine, Imke Satzger, Weder, Patrik, Ullrich Keller (103650), Lucie M. Heinzerling (103723), Gerold Schuler (103690), Axel Hauschild (103637), Christina Klein (103657), Michael Fluck, Tanja Bergmann (103612), Axel Hauschild, Paetzold Sylvie, Katharina C Kaehler, Wilhelm Tabea, Keller, Ullrich, Schlaeppi Marc, Goldinger, Simone M., Claus Garbe (48881), Berking Carola, Heinzerling, Lucie, von Moos Roger, Simone M Goldinger, Trefzer Uwe, Uwe Trefzer (72075), Rüdiger Hein, Mateus, Christine, Caroline Robert, Tabea Wilhelm (103712), Schuler Gerold, Dummer, Reinhard, Schuler-Thurner Beatrice, Roger von Moos, Hein Rüdiger, Eigentler, Thomas, Paetzold, Sylvie, Caroline J Voskens, Caroline J. Voskens (103590), Schuler-Thurner, Beatrice, Roger von Moos (103705), Patrik Weder (103709), Lucie M. Heinzerling, Kaehler, Katharina C, Voskens, Caroline J., Fluck, Michael, Imke Satzger (103681), Schuler, Gerold, Tanja Bergmann, Marc Schlaeppi (103687), Bergmann, Tanja Regina, Julia Vaubel (103700), Bergmann Tanja, Heinzerling, Lucie M., Stephan Grabbe, Klein Christina, Caroline Robert (103600), Carola Berking (103608), Kähler, Katharina C., Peter Mohr (103669), Klein, Christina, Tabea Wilhelm, Reinhard Dummer (103718), Goldinger Simone M., Reinhard Dummer, Marc Schlaeppi, Gutzmer, Ralf, Hein, Rüdiger, Clemens L Bockmeyer, Sylvie Paetzold, Michael Fluck (103622), Kaehler Katharina C., Justich Armin, Voskens Caroline J., Carmen Loquai, Vaubel Julia, Grabbe Stephan, Keller Ullrich, Mohr Peter, Jens Ulrich (103696), Trefzer, Uwe, Katharina C. Kaehler (103604), Bergmann, Tanja, Heinzerling Lucie M., Dummer Reinhard, et al, Goldinger, Simone M, Daniela Göppner (103715), Garbe, Claus, Clemens L. Bockmeyer (103616), Schlaeppi, Marc, Ullrich Keller, von Moos, Roger, Voskens, Caroline J;Goldinger, Simone M;Loquai, Carmen;Robert, Caroline;Kaehler, Katharina C;Berking, Carola;Bergmann, Tanja;Bockmeyer, Clemens L;Eigentler, Thomas;Fluck, Michael;Garbe, Claus;Gutzmer, Ralf;Grabbe, Stephan;Hauschild, Axel;Hein, Rüdiger;Hundorfean, Gheorghe;Justich, Armin;Keller, Ullrich;Klein, Christina;Mateus, Christine;Mohr, Peter;Paetzold, Sylvie;Satzger, Imke;Schadendorf, Dirk;Schlaeppi, Marc;Schuler, Gerold;Schuler-Thurner, Beatrice;Trefzer, Uwe;Ulrich, Jens;Vaubel, Julia;von Moos, Roger;Weder, Patrik;Wilhelm, Tabea;Göppner, Daniela;Dummer, Reinhard;Heinzerling, Lucie M +160 morecore +2 more sourcesCTLA-4 Antibodies in Cancer Immunotherapy
, 2016 Activating human immune system to battle cancer has been a focus of cancer immunotherapy research from quite some time. After decades of disappointment, the tide has finally changed with some recent successes in clinical trials.Veerendra Koppolu (3073263)core +1 more source